The Value of Mean Platelet Volume in Predicting The Severity of Preeclampsia and of Hellp Syndrome

OBJECTIVE: Assessing the value of MPV in predicting the severity of preeclampsia, and HELLP syndrome. STUDY DESIGN:12 women with HELLP syndrome,57 severely preeclamptic,30 mildly preeclamptic, 170 healthy pregnant women were included in this study and their MPV are recorded. RESULTS: The calculated sensitivity was 53% for mild preeclampsia,77% for severe preeclampsia, and 83% for HELLP syndrome. CONCLUSION: The measurement of MPV is not enough for diagnosis but can be useful with other sensitive tests

Age- and body mass index-dependent relationship between correction of iron deficiency anemia and insulin resistance in non-diabetic premenopausal women

<b>Background: </b> No prospective studies have evaluated the effects of correction of iron deficiency anemia on insulin resistance in non-diabetic premenopausal women. We investigated this relationship in 54 non-diabetic premenopausal women with iron deficiency anemia. <b>Subjects and Methods: </b>All patients were treated with oral iron preparations. Insulin resistance was calcu-lated with the Homeostasis Model Assessment formula. All patients were dichotomized by the median for age and BMI to assess how the relationship between iron deficiency anemia and insulin resistance was affected by age and BMI. <b> Results: </b> Although the fasting glucose levels did not change meaningfully, statistically significant decreases were found in fasting insulin levels following anemia treatment both in the younger age (&#60; 40 years) (P=0.040) women and in the low BMI (&#60; 27 kg/m² ) (P=0.022) subgroups but not in the older age (240 years) and the high BMI (227 kg/m² ) subgroups. Post-treatment fasting insulin levels were positively correlated both with BMI (r=0.386, P=0.004) and post-treatment hemoglobin levels (r=0.285, P=0.036). Regression analysis revealed that the factors affecting post-treatment insulin levels were BMI (P=0.001) and post-treatment hemoglobin levels (P=0.030). <b> Conclusion: </b>Our results show that following the correction of iron deficiency anemia, insulin levels and HOMA scores decrease in younger and lean non-diabetic premenopausal women

The Effects of Risedronate Therapy Combined With Vitamin D and Calcium on Biochemical Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporosis

The aim of the study was to investigate the effects of risedronate therapy combined with vitamin D and calcium on bone mineral density(BMD) and biochemical markers of bone turnover in patients with primary postmenopausal osteoporosis. Fifty osteoporotic postmenopausal women were included in our study. All patients were given daily doses of 5 mg risodronate, 1000 mg elementary calcium and 500 IUvitamine D during 1 year study period. Dual Energy X-ray Absorbsimetry was used for the measurement of BMD’s of the lumbar spine and proximal femur. In addition calcium, magnesium, phosphorus, ALP, tartarat resistant acid phosphotase (TRAP), osteocalcine levels were measured in blood and C-telopeptides(CTX1) in the urine samples . There were no significant changes in serum levels of magnesium, phosphorus and TRAP after one year of therapy. Calcium and ALP levels were lower than baseline. Osteocalcine and CTX levels were found to be decreased significantly. Lomber and proximal femur BMD’s were found to be significantly increased at the end of one year. Our results demonstrated that risedronate therapy combined with calcium and vitamin D for postmenopausal primary osteoporosis results in significant increases in spinal and femur BMD’s. This result was supported by changes in biochemical marker levels of bone turnover as well